

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: 08/21/2002 (use as many sheets as necessary)				Complete if Known	
				Application Number	10/049,373
				Filing Date	06/21/2002
				First Named Inventor	Isao ISHIDA et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	051023-0115
Sheet	1	of	3		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁹
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
TNT	A1	WO	98/37757	A1	Tomizuka et al.	3/09/1998		abs

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁹	
TNT	A2	TOMIZUKA et al., EP0773288 A3, July 9, 1997, <u>Abstract</u> .		
TNT	A3	RAMSDEN, R. et al., "Phenobarbital Induction and Tissue-specific Expression of the Rat CYP2B2 Gene in Transgenic Mice", <u>J. Biol. Chem.</u> , 268 (222): 21722-2176 (1993).		
TNT	A4	KAMATAKI, T. et al., "Application of Molecular Technology to Drug Metabolism Studies: Perspectives", <u>Yakubutsu Douei</u> , 13(3): 280-288 (1997)	yes	
TNT	A5	NELSON et al., "P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature," <u>Pharmacogenetics</u> , 6: 1-42, (1996).		

Examiner Signature		Date Considered	2/18/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁹ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002,642227.1

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/049,373
				Filing Date	08/21/2002
Date Submitted: 06/21/2002				First Named Inventor	Isao ISHIDA et al.
				Group Art Unit	Unassigned
(use as many sheets as necessary)				Examiner Name	Unassigned
				Attorney Docket Number	051023-0115
Sheet	2	of	3		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
TNT	A6	TOMIZUKA, K. et al., "Functional Expression and Germline Transmission of a Human Chromosome Fragment in Chimeric Mice", <u>Nature Genetics</u> , 16: 133-143 (1997).		
	A7	JAKOBOVITS, A. et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome", <u>Nature</u> , 382: 255-258 (1993).		
	A8	SHIINA, T. et al., "Nucleotide Sequencing Analysis of the 146-Kilobase Segment Around the <i>IKBL</i> and <i>MICA</i> Genes at the Centromeric End of the HLA Class 1 Region", <u>Genomics</u> , 47: 372-382 (1998).		
	A9	HUBERT, R. et al., "BAC and PAC Contigs Covering 3.5 Mb of the Down Syndrome Congenital Heart Disease Region Between D21S55 and MX1 on Chromosome 21", <u>Genomics</u> , 41: 218-226 (1997).		
	A10	ZHI-WEI, LI et al., "Generation of Mice with a 200-kb Amyloid Precursor Protein Gene Deletion by Cre Recombinase-Mediated Site-Specific Recombination in Embryonic Stem Cells", <u>Proc. Natl. Acad. Sci. USA</u> , 93: 6158-6161 (1996).		
	A11	GU, H. et al., "Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", <u>Science</u> , 265: 103-108 (1994).		
	A12	LI, Y., et al., "Establishment of Transgenic Mice Carrying Human Fetus-Specific CYP3A7", <u>Archives of Biochemistry and Biophysics</u> , 239 (2): 235-240 (1996).		
	A13	KAMATAKI, T. et al., "Expression of CYP3A7, a Human Fetus-Specific Cytochrome P450, in cultured Cells and in the Hepatocytes of p53-Knockout Mice", <u>Toxicology Letters</u> , 82/83: 879-882 (1995).		
	A14	KOVALEVA, I. et al., "Transgenic Yeast Expressing Human Cytochrome P450s Can Serve as a Tool in Studies of the Mechanisms of their Induction by Various Effectors", <u>Biochemical and Biophysical Research Communications</u> , 221(1): 129-132 (1996).		
	A15	GILLAM, E. et al., "Expression of Modified Human Cytochrome P450 3A4 in <i>Escherichia coli</i> and Purification and Reconstitution of the Enzyme", <u>Archives of Biochemistry and Biophysics</u> , 305(1): (1993).		
	A16	ASSEFFA, A. et al., "Novel Exogenous Heme-Dependent Expression of Mammalian Cytochrome P450 Using Baculovirus", <u>Archives of Biochemistry and Biophysics</u> , 274(2): 481-490 (1989).		
	A17	SHOU, M. et al., "The Role of 12 cDNA-Expressed Human, Rodent, and Rabbit Cytochromes P450 in the Metabolism of Benzo[a]pyrene and Benzo[a]pyrene trans, 7-8-Dihydrodiol", <u>Molecular Carcinogenesis</u> , 10: 159-168 (1994).		
	A18	WOLF, C., et al., "Use of Transgenic Animals in Understanding Molecular Mechanisms of Toxicity", <u>J. Phar. Pharmacol.</u> , 50: 567-574 (1998).		
	A19	McKINNON, R. et al., "Cytochrome P450 Knockout Mice: New Toxicological Models", <u>Clinical and Experimental Pharmacology and Physiology</u> , 25: 783-787 (1998).		
TNT	A20	PINEAU, T. et al., "Neonatal Lethality Associated with Respiratory Distress in Mice Lacking Cytochrome P450 1A2", <u>Proc. Natl. Acad. Sci. USA</u> , 92: 5134-5138 (1995).		

Examiner Signature	<i>Trace</i>	Date Considered	2/18/05
--------------------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.842227.1

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: 06/21/2002 (use as many sheets as necessary)			Complete if Known		
			Application Number	10/049,373	
			Filing Date	06/21/2002	
			First Named Inventor	Isao ISHIDA et al.	
			Group Art Unit	Unassigned	
			Examiner Name	Unassigned	
			Attorney Docket Number	051023-0115	
Sheet	3	of	3		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
TNT	A21	LIANG, H. et al., "Cyp1a2(-/-) Null Mutant Mice Develop Normally but Show Deficient Drug Metabolism", <u>Proc. Natl. Acad. Sci. USA</u> , 93: 1671-1676 (1996).		
	A22	GENTER, M. et al., "Role of CYP2A5 and 2G1 in Acetaminophen Metabolism and Toxicity in the Olfactory Mucosa of the Cyp1a2(-/-) Mouse", <u>Biochemical Pharmacology</u> , 55: 1819-1826 (1998).		
	A23	LEE, S. et al., "Role of CYP2E1 in the Hepatotoxicity of Acetaminophen", <u>The Journal of Biological Chemistry</u> , 271: 20, 12063-12067 (1996).		
	A24	FUNAE, Y. et al., "Drug Metabolism by Human Cytochrome P 450", <u>Bioscience and Industry</u> , 55: (2): 81-86 (1997).	partial	
	A25	KAMATAKI, T. et al., "Reports of Anhyo Center Laboratory", <u>Incorporated Foundation</u> , 7: 27-33 (1997).	partial	
	A26	ISHIDA et al., "Introduction to Cell Engineering, Experiment Manipulation", <u>Kodansha Publishing</u> , 39: lines 1-4 (1992).	partial	
	A27	AIZAWA, S. "Gene Targeting", <u>Biomanual Series 8</u> , Yodosha : 89-105 (1995).		
TNT	A28	SHIMUZU, M., "III Chromosome and Gene Mapping 7, Method for Introduction of Human Chromosome by Microcell Fusion", <u>Cell Engineering Handbook</u> , Yodosha : 127-132 (1992).	partial	

Examiner Signature	<i>tharon</i>	Date Considered	2/15/05
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.